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INTRODUCTION
It is estimated that one-third of HIV-infected per-
sons in the European Union and one in every five
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in the United States do not know their serologi-
cal status (Deblonde et al., 2011). Those diagnosed
with advanced immune deficiency are known to
suffer greater morbidity and mortality (Moreno et
al., 2010). Moreover, persons who are unaware of
their infection have a transmission rate 3.5 times
higher than those who know their serological sta-
tus (Thompson et al., 2010; Borghi et al., 2008).
Thus, the earliest possible diagnosis is one of the
most efficient strategies to control the epidemic,
and is currently a priority for all infection con-
trol plans (National HIV/AIDS Policy, 2010).
The submerged portion of undiagnosed HIV infection in Italy is about 30% of subjects found seropositive. This fact
represents one of the most important public health problems hindering the control of infection progression. This
means we need to fight unawareness and social stigma and promote easy and friendly access to HIV test. We devel-
oped a Prevention Program called “EASY test Project”, offering a new rapid HIV test on oral fluid, to evaluate the ac-
ceptability of an alternative, free and anonymous test available in different settings (on board a “Motor Home” at pub-
lic events, Points of Care, STDs outpatient prevention units and GP surgeries). From December 2008 to December 2012
we performed 7,865 HIV saliva tests, with 50 new infections found (0.6% of the total) out of 140,000 informed sub-
jects. From the self-reported characteristics of respondents, the population approaching the EAST test project was rep-
resented by males (70%) aged between 20 and 50 years, 61% with a medium-high education level, 62% homosexuals
(MSM), 88% reported unsafe sexual behaviours, and 48% had never undergone an HIV screening test. In five years
of the Prevention Program, 100% of subjects interviewed gave a general favorable consent in approaching rapid and
not invasive screening, immediate return of the result, and a timely specialized approach and treatment of HIV pos-
itive subjects. Results from our study confirm that the rapid and alternative test may contribute to HIV prevention strate-
gies and to the control of the spread of infection and HIV disease progression by reaching a larger population, par-
ticularly when and where regular screening procedures are difficult to obtain or are not preferred.
KEY WORDS: HIV screening test, Late HIV diagnosis, Saliva/oral fluid test, HIV positive submerged people, HIV pre-
vention.
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To date in Italy, the submerged portion of undi-
agnosed HIV infection in Italy is probably about
30% (30-50,000) of seropositive subjects. This fact
represents one of the most important public
health problems in the field of sexually transmit-
ted diseases (STDs), as is the main deterrent to
controlling the progression of the infection to the
disease and the spread of the HIV epidemic
(D’Amato et al., 2010). Failure or delay in the di-
agnosis of infection make it difficult to establish
a timely and effective treatment and the imple-
mentation of all the provisions of appropriate
prophylaxis to prevent HIV transmission
(Antinori et al., 2010). Timely and effective treat-
ment, and the implementation of the prophylax-
is guidelines to prevent the transmission of HIV
infection are not possible when the diagnosis of
HIV infection is missed or late. Although the cur-
rent legislation in Italy and the offer of conven-
tional testing by taking blood samples should the-
oretically be able to guarantee all citizens, the op-
portunity to obtain a diagnosis of infection free of
charge, in reality, individual preference, the pro-
cedures and rules for the implementation of test-
ing currently do not solve the problem of “hid-
den” infection (http://www.salute.gov.it).
For many years, the European Community has
advocated that countries should facilitate access
to testing, but for various reasons, individual
countries can provide only few programs or mod-
els of intervention aimed at increasing diagnosis
in high risk populations.
In recent years, inadequate information and pre-
vention campaigns in Italy, the medicalization of
the tests and the fear of the dreaded diagnosis
have contributed to stay away from the test and
to raise the proportion of submerged infection
(WHO, 2011).
Several studies conducted in the last 15 years
have shown that the frequency of late diagnosis
of HIV infection in industrialized countries varies
between 15% and 43%. According to data pro-
vided by the Italian multicentre study Italian
Cohort Näive Antiretrovirals (I.Co.NA.), of the 968
patients enrolled from 1997 to 2000, 29% received
a diagnosis of infection after developing an AIDS-
defining illness or condition due to an already ad-
vanced immunosuppression (CD4 + lymphocyte
count <200 cells/mmc, defined as Advanced
Näives or AIDS Presenters or symptomatic sub-
jects) (Girardi et al., 2004). There is a strong need
to increase awareness, reduce social stigma and
facilitate the access to HIV testing. For many
years this issue represents the European com-
munity goal. It is clear that no single prevention
approach alone will be effective and relevant to all
populations across Italy. However, strategic ac-
tions should be implemented to guide prevention
programme planning and development. 
Testing policies are undergoing extensive review
in many countries and international agencies
(http://www.salute.gov.it). All new versions are
moving toward ending the “exceptionalism” that
previously guided them to facilitate test access.
The most interesting tool among the new strate-
gies is the use of rapid and point of care tests in
different contexts, including non-clinical settings.
These tests are easy to use and provide results
within 30 minutes, including counselling (CDC,
2011). The tests available require samples of oral
fluid or blood. Although the accuracy may be low-
er than current reference laboratory serology, the
specificities and sensitivities of HIV rapid test kits
are high and are comparable to first and second
generation conventional EIAs (De la Fuente et al.,
2012).
The widespread use of a rapid test on oral fluid,
with immediate result, is also considered one of
the most important tools to reduce the propor-
tion of people who do not return to pick up the re-
sults of the test (“failure to return”). In fact, among
those who are tested conventionally, a high per-
centage fail to return to collect their results. In
contrast, studies conducted using the rapid test
showed that the percentage of failure to return
in some cases is even zeroed (Marks et al., 2006).
Currently in Europe, rapid HIV tests cannot be
sold over the counter for self-testing, but the US
Food and Drug Administration (FDA) recently
approved the OraQuick In-Home HIV test, based
on trials conducted by the manufacturer (FDA,
2012). It should be considered that a device for
self-testing not free of charge could be the first
limit for an extensive use in Italy.
Some authors have proposed that self-testing can
be an innovative component of community-wide
HIV prevention strategies by providing testing to
persons who, for reasons of stigma or confiden-
tiality, do not wish to reveal their sexual practices;
such persons could be tested when they perceive
they are at risk of infection, something they may
not feel they need again for a long time (Spielberg
122 M.R. Parisi et al.
et al., 2004; Frith et al., 2007; Vv.Aa., 2002; Merson
et al., 1997). 
On the other hand, Walensky et al. (2006) em-
phasized the possibility that the availability of
self-testing devices would lead to a dangerous
stress caused by the immediacy of a possible pos-
itive result in individuals carrying out self-testing
without training or psychological assistance. 
Few studies have addressed this topic, but one did
not incorporate interpretation and included only
seropositive individuals, and another one was con-
ducted mostly in this group and showed disap-
pointing results (Spielberg et al., 2003). Another
study reported very good results, but participants
either had seen how they were tested immediate-
ly before they performed their own self-test, or
performed their own test after a demonstration
by a counsellor (Choko et al., 2011). 
In 2008, the Infectious Diseases Department of
San Raffaele Scientific Institute in Milan devel-
oped a Prevention Program called the “EASY test
project”, initially to evaluate the quality charac-
teristics of a saliva test under development, with
very interesting results. However, the manufac-
turer did not continue with the registration in
Europe (Parisi et al., 2009). 
The same project subsequently continued using a
new test, the OraQuick Advance HIV-1/2 (Orasure
Technologies Inc.). The OraQuick blood test was
first approved in 2002 by the FDA, and in 2004 re-
ceived approval for use with oral fluid. Today it is
globally used in clinics and emergency rooms and
outreach community testing schemes (http://
www.orasure.com). 
To date, the main objectives of our work are no
longer to test the reliability of the oral fluid rapid
tests (sensitivity and specificity), but to evaluate
the acceptability of an alternative, free and anony-
mous HIV test offer, available in different settings
(on board a “Motor Home” at public events, Points
of Care, STDs outpatient prevention units and GP
surgeries). Furthermore, reaching people with this
anonymous and free test offer could reduce or
stop this public health problem.
From 2008 to date, the EASY test project has been
implemented at various times and locations. The
first experience was in 2008 using a mobile unit in
Turin, followed by public events and prevention
programs in Milan in 2009 (Convivio, Le piazze
della salute) (http://www.conviviomilano.it/). The
“Motor Home” (MH), had four working rooms to
offer the general population privacy while wait-
ing and during the three different steps. 
In 2010, the project evolved and the rapid oral
test became regularly available in three different
locations in Milan: on the first Friday of the
month in two San Raffaele Point-of-Care sites
and one STDs Public Prevention Clinic (“FreeDay
Easy-test”); and has now been extended to six GP
surgeries.
The MH program continues to conduct outreach
testing twice a year during the Prevention
Program of Milan City (“Le piazze della Salute
2010”) and on 1st December on International
World AIDS Day.
Individuals are counselled by an infectious dis-
eases specialist or by a psychologist and sign an
Informed Consent Form before taking the test.
In addition, for individuals who do not wish to
participate in the study, the test was offered free
and anonymously with an identification code for
subsequent evaluation of the results.
This report summarizes EASY test data collected
from 2008 to date for the individuals who par-
ticipated in the EASY test study (100% of all tests
offered).
METHODS
This program has been running since 2008 with
the aim of promoting HIV early diagnosis using
a rapid and non-invasive oral fluid antibody test.
This is a cross-sectional community study, im-
plemented with the support of the Infectious
Diseases Department of San Raffaele Hospital, in
collaboration with Milan Council, Department of
Prevention-Reference Centre for HIV and STDs
(Local Public Health Unit in Milan), L. Sacco
Hospital of Milan, and supported by ANLAIDS-
Lombardia association (National Association for
the Fight against AIDS). 
The study was conducted in Milan between
December 2008 and December 2012 on four dif-
ferent occasions:
1. Convivio ANLAIDS-Lombardia;
2. Milan Council (“L’anno della salute”, “Le piazze
della salute”, “1st December AIDS World Day”);
3. Two Points of Care at San Raffaele Hospital
and one HIV-STDs Public Prevention Clinic
(“FreeDay Easy”); 
4. Six GP surgeries.
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During each of these appointments, the work
team at San Raffaele Hospital, composed of an
infectious diseases specialist and two biologists,
with one psychologist and many volunteers from
the ANLAIDS-Lombardia association, carried out
the EASY test project on board the MH, sup-
ported by the work team at L. Sacco Hospital in
Milan.
On board the MH there were four different spaces
to guarantee the privacy of subjects performing
the test: a waiting room with STDs prevention in-
formation, a pre-test counselling room, a testing
room, and a room for giving back results (even-
tually blood sampling) and post-test counselling.
This so-called “Street Lab” is as close as possible
to a traditional laboratory, but the HIV test offer
was free of charge and anonymous for the study
participants. 
One of every two subjects approached the Easy
test locations just to collect information on HIV
prevention and transmission.
A psychologist explained the study objectives and
procedures to all participants and each of them
signed an informed consent form. Each subject
was allocated an identification code number for
testing. Subjects who underwent the test were
asked to complete an anonymous questionnaire,
through which it was possible to collect a series
of data on risk behaviours of the population test-
ed. The questionnaire was intended to collect de-
mographic and risk behaviour data, as well as
previous HIV testing experience, questions about
sex, educational level, nationality, drug use, HIV
testing behaviours and use of HIV prevention
services. 
Recruitment criteria/ Study enrollment
People eligible for enrollment in the project were
aged >18 years, unaware of their HIV-1 serologi-
cal status and able to complete the questionnaire
in Italian or in English. Subjects were informed
that they could refuse testing at any time. Post-
test counselling was provided to all HIV reactive
and non-reactive subjects by the Infectious
Diseases Department physicians involved in the
study.
All those with an HIV reactive test were offered
free regular screening (IV generation ELISA fol-
lowed by Western blot confirmation), and the re-
sults and their first specialist infectivology visit
were guaranteed within a few days.
Performing the test
The testing step was carried out by a biologist or
a practitioner following the manufacturer’s in-
structions.
The first year of the project was carried out using
the RAPID TEST HIV® Lateral flow (HealthChem
Diagnostics LLC, Pompano Beach, FL, USA).
This is a membrane-based solid phase assay that
contains antigens capturing the antibodies from
a plasma, serum or saliva sample. 
Following the discontinuation of the RAPID
TEST HIV® Lateral flow, in 2009 our prevention
program was performed using the new OraQuick
ADVANCE® Rapid HIV-1/2 Antibody Test
(OraSure Technologies, Bethlehem, PA, USA). 
This test is a single-use qualitative immunoassay
to detect antibodies to Human Immunodeficiency
Virus Type 1 (HIV-1) and Type 2 (HIV-2) in oral
fluid, fingerstick whole blood, venipuncture
whole blood and plasma specimens. On the oral
fluid the test sensitivity is 99.3%, the specificity is
99.8%, with 95% Confidence Interval (http://www.
orasure.com).
It is very important to follow the manufacturer’s
sampling procedure (saliva collection), because
this step can affect the proper performance of the
test, resulting in false positive test results. The
test is interpreted by a trained biologist or physi-
cian. If the HIV oral test is non-reactive, the post-
test counselling discusses the prevention of trans-
mission and other safe behaviours to prevent
STDs. If the HIV oral test is reactive, a rapid
blood test (VIKIA® HIV-1/2, Biomèrieux
Diagnostics) is performed immediately, support-
ed by post-test counselling to interview the sub-
ject about possible previous risk behaviours and
to prepare them for an HIV-positive diagnosis. If
both Point of Care rapid tests are reactive, then a
blood sample is collected and sent to the serolo-
gy laboratory of San Raffaele Hospital for stan-
dard ELISA and confirmed by Western Blot test-
ing procedures. The results are received in four to
five days. At this point, the HIV-positive patient is
contacted directly by the infectious diseases spe-
cialist to start the process of HIV diagnosis and
eventually treatment.
Ethical committee
The project protocol was approved by the
Institutional Review Board of the Ethics
Committee of San Raffaele Hospital in Milan. An
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informed consent form was prepared explaining
the details of the study, the HIV testing procedure
and the interventions available for the individual.
This information was also orally communicated
(pre-test counselling) to the subjects by the per-
sonnel performing the test. 
Data collection and analysis
HIV test results are entered immediately into a
personal electronic file by the biologist responsi-
ble. Study data, including the questionnaires, are
conveyed to the Department of Infectious
Diseases of San Raffaele Hospital, used anony-
mously under the control of the Head of the proj-
ect and the Department. Anonymity is guaran-
teed by assigning to each subject taking the oral
test an identification code, of which only the
Head of the Department has access for further
correspondence.
RESULTS
From December 2008 to December 2012, 140,000
subjects were approached to inform them about
HIV infection and other STDs; 7,865 (5.6%) total
eligible volunteers underwent HIV tests on saliva
and completed the interview in the alternative
“street lab” (Table 1). The remaining non-respon-
dents comprised a small number who knew about
the alternative test but did not use it reporting fear
the results could be less accurate, and others who
were unaware of their risk transmission and pre-
ferred not to know their serological status.
The total number of subjects tested during the
last five years varied and gradually increased due
to the different events carried out each year. In
the first two years there were few EASY test
events, while from 2010 to 2012 the largest num-
ber of events was organized (Convivio, public
events of Milan Council, HIV-STDs Prevention
Units and GP surgeries) consequently broaden-
ing access to the service.
A high percentage of subjects undergoing month-
ly HIV saliva tests appears to be represented, on
the one hand, by those with a high and altered
perception of risk needing to test themselves re-
peatedly, sometimes obsessively, while not hav-
ing at-risk sexual behaviours sexual risk. On the
other, there are those who are aware and prefer
to test themselves to continue their sexual activ-
ity at risk but with a clear conscience after hav-
ing the negative result.
The portrait of the population responding to the
EASY test initiative in these five years is quite var-
ied but dominated by Italian men aged between 20
and 50 years, with a medium-high level of educa-
tion (graduates, managers, 61%), 62% of them ho-
mosexuals (MSM), 38% high-risk heterosexuals
(HRH) and only one of the total (0.01%) trans-
gender. 52% of subjects had never performed a
test for HIV for fear of knowledge or a lack of risk
perception, despite claiming to have consistently
high-risk sexual behaviours (Table 1).
In the first year of the initiative (2008), 761 saliva
tests were performed, 40 of which on African HIV-
positive pregnant women considered as a control
group at St. Francy’s Nsambya Hospital of
Kampala in Uganda. Each of 761 tests performed
was confirmed immediately by the blood screen-
ing test (ELISA), then confirmed by the conven-
tional test (Western Blot). Almost all HIV-positive
and negative subjects were confirmed by the re-
active and non-reactive saliva rapid tests respec-
tively. Only one reactive saliva test was confirmed
by conventional screening test (0.1%, 1/761), four
false positives and one false negative results were
obtained, probably due to the poor reliability of
that oral test used, at that time not FDA approved.
The lower prevalence of the test performed (0.1%)
is probably related to the test used.
As can be seen from the Table 1, in 2008, 51% of
761 tested subjects were Italian females, with a
high level of education (50%), employed, aged be-
tween 19 and 40. More than 50% of the total were
students, with 80% having had unsafe sex and,
in 50% of cases, this represented the first ap-
proach to HIV testing.
After the first encouraging numbers of 2008 pub-
lished by Parisi et al. (2009), the EASY test pre-
vention program continued with the same objec-
tives, but using the new rapid saliva test, FDA and
Ethical Committee approved, the OraQuick AD-
VANCE HIV-1/2 Rapid test (OraSure Techno -
logies, Bethlehem, PA, USA). 
The EASY test project was performed during the
public Prevention Program of the City of Milan
called “L’anno della salute 2009” with a MH
parked around the City of Milan, and in the first
GP surgery in Milan (the pilot study). 
By analyzing the population tested for a single
year of the initiative, a total of 936 rapid saliva
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tests were performed in 2009, and 54,000 book-
lets were distributed. A total of 12 new HIV in-
fections were detected out of 936 tested (1.2%). 
The population tested was similar to the previ-
ous year: almost an half of them were male (59%),
coming from Italy (32%), with a low educational
level and a median age of 35 years old. 31% were
MSM and 69% HRH, 80% reported unsafe sex
but only 35% had been previously tested. During
2010, a total of 1,841 rapid saliva tests were per-
formed. 0.16% (3/1.841) of rapid saliva tests were
positive and 60,000 booklets were distributed to
the population.
Starting in 2010, the patient demographic data
of our project changed: the percentage of males
taking the test increased (71%) as did the per-
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TABLE 1 - Self-reported demographic characteristics of eligible respondents among individuals interviewed
from December 2008 to December 2012, per year.
2008 2009 2010 2011 2012 Total
N. Informed subjects (Test offer days) 2.000 54.000 60.000 14.000 10.000 140.000
(15 days) (24 days) (27 days) (26 days) (25 days) (117 days)
N. Tested subjects (percentage of informed) 761 936 1.841 1.931 2.396 7.865
(38%) (1.74%) (3%) (13.8%) (24%) (5.6%)
N. HIV+ saliva test (percentage of tested) 1 12 3 12 22 50
(0.1%) (1.2%) (0.1%) (0.6%) (0.9%) (0.63%)
Gender: 
Male 373 (49%) 553 (59%) 1.306 (71%) 1.408 (73%) 1.916 (80%) 5.556 (70%)
Female 388 (51%) 383 (41%) 534 (29%) 523 (27%) 480 (20%) 2.308 (30%)
Transgender 0 0 1 (0.05%) 0 0 1 (0.01)
(percentage of tested)
Education: 
High level school 380 281 921 1.545 1.677 4.804
(percentage of tested) (50%) (30%) (50%) (80%) (70%) (61%)
Employment:
Workers 304 113 1.141 1.641 2.108 5.307
(percentage of tested) (40%) (12%) (62%) (85%) (88%) (67%)
Median age 30 35 35 35 35 34
(Range) (19-40) (20-50) (20-50) (20-50) (20-50)
Race:
Italian 396 300 737 580 1.437 3.450
(percentage of tested) (52%) (32%) (40%) (30%) (60%) (44%)
HIV Risk status:
MSM* 300 (40%) 293 (31%) 1.287 (70%) 1.267 (65%) 1.724 (72%) 4.871 (62%)
HRH** 461 (60%) 643 (69%) 553 (30%) 664 (35%) 672 (28%) 2.993 (38%)
Transgender 0 0 1 (0.05%) 0% 0% 1 (0.01)
(percentage of tested)
Unsafe sex 609 750 1.694 1.738 2.156 6.947
(percentage o tested) (80%) (80%) (92%) (90%) (90%) (88%)
Previous tested 380 328 552 1.216 1.557 4.033
(percentage of tested) (50%) (35%) (30%) (63%) (65%) (52%)
*Male who have Sex with Male; **High-Risk Heterosexual.
centage of MSM (70%), with 50% having a medi-
um-high level of education. We also tested a
member of the transgender community (0.05%,
1/1.841), who resulted HIV-negative. 92% of sub-
jects reported at-risk sexual behaviours and only
30% had had a previous HIV test (Table 1). 
During 2011, 1,931 total rapid oral tests were per-
formed (14,000 information packages were dis-
tributed), and 12 (0.6%) reactive tests were found
and confirmed positive by the blood test. A new
and fixed appointment took place each first
Friday of the month from February to December
called “FreeDay EASY test 2011”: two San Raffaele
Points of Care, located in two different points of
the City, and one HIV-STDs Prevention Unit were
dedicated to prevention, counselling and screen-
ing for HIV infection. Most people who under-
went the test were male (73%), 65% of whom
were MSM, with high-risk behaviours (90% of
unsafe sex), workers with a high level of educa-
tion (85%), aged between 20 and 50 years.
Also during this last year 2012, the San Raffaele
initiative of FreeDay EASY test was started in
February and finished in December. A total of
2,396 saliva tests were performed in 2012 and 22
(0.9%) new HIV infections diagnosed. 65% of
those who participated in the EASY test project
had had a previous test for HIV, and half of them
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TABLE 2 - Self-reported demographic characteristics of HIV-positive saliva test subjects per year, 
from December 2008 to December 2012.
2008 2009 2010 2011 2012 Total
N. HIV+ saliva test 1 12 3 12 22 50
Gender: 
Male 1 (100%) 12 (100%) 3 (100%) 12 (100%) 22 (100%) 50 (100%)
Female 0 0 0 0 0 0
Transgender 0 0 0 0 0 0
(percentage of tested)
Education: 
High level school 0 5 2 4 19 30 
(percentage of tested) (42%) (67%) (34%) (86%) (60%)
Employment:
Workers 0 5 2 10 19 36 
(percentage of tested) (42%) (67%) (84%) (86%) (72%)
Median age  (Range) 25 30 30 37.5 37.5 32
(20-40) (20-40) (25-50) (25-50) median age
Race:
Italian 0 6 1 10 19 36
(percentage of tested) (50%) (34%) (84%) (86%) (72%)
HIV Risk status:
MSM* 1 (100%) 7 (58%) 3 (100%) 10 (84%) 22 (100%) 43 (86%)
HRH** 0 5 (42%) 0 2 (16%) 0 7 (14%)
Transgender 0 0 0 0 0 0
(percentage of tested)
Unsafe sex 1 10 3 10 22 46
(percentage o tested) (100%) (84%) (100%) (84%) (100%) (92%)
Previous tested 0 2 0 4 10 16
(percentage of tested) (16%) (34%) (46%) (32%)
*Male who have Sex with Male. **High-Risk Heterosexual.
chose our FreeDay as the usual date to undergo
screening after having unsafe sexual behaviours.
80% of total tested subjects were male with a high
level of education, in employment and aged be-
tween 20 and 50. 72% of the subjects, in this last
year, comprised MSM who reported consistently
unprotected sex (90%) (Table 1). 
Regarding the 50 (0.6% of the total) subjects who
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TABLE 3 - Self-reported demographic characteristics of eligibles respondents among individuals interviewed
from December 2008 to December 2012, per different location.
Convivio Public events San Raffaele General Total
ANLAIDS of Milan City Point of care Practitioner
(2008-2012) and 1° December and HIV-STDs ambulatories
AIDS World Day Prevention (2010-2012)
(2008-2012) ambulatory 
(2010-2012)
N. Subjects informed 34.000 45.000 52.000 9.000 140.000
on STD prevention
N. Tested subjects 1.582 2.276 3.738 269 7.865 
(percentage of informed) (4.6%) (5%) (7%) (2.9%) (5.6%)
N. HIV+saliva test 11 12 22 5 50
(percentage of tested) (0.7%) (0.5%) (0.6%) (1.8%) (0.63%)
Gender: 
Male 900 (57%) 1.700 (75%) 2.806 (75%) 150 (56%) 5.556 (70%)
Female 682 (43%) 576 (25)% 932 (25%) 118 (44%) 2.308 (30%)
Transgender 0 0 0 1 (0.3%) 1 (0.01)
(percentage of tested)
Education: 
High level school 600 1.204 2.800 200 4.804
(percentage of tested) (38%) (53%) (75%) (74%) (61%)
Employment:
Workers 767 1.300 2.980 260 5.307
(percentage of tested) (48%) (57%) (80%) (62%) (67%)
Median age 
(Range) 25 (20-30) 30 (20-40) 35 (20-45) 46 (30-62) 34 median age
Race:
Italian 560 (35%) 1.138 (50%) 1.552 (42%) 200 (74%) 3.450 (44%)
(percentage of tested)
HIV Risk status:
MSM* 900 (57%) 1.266 (56%) 2.700 (72%) 5 (1.8%) 4.871 (62%)
HRH** 682 (43%) 1.010 (45%) 1.038 (28%) 263 (97.9%) 2.993 (38%)
Transgender 0 0 0 1 (0.3%) 1 (0.01)
(percentage of tested)
Unsafe sex 
(percentage o tested) 947 (60%) 2.260 (99%) 3.660 (98%) 80 (30%) 6.947 (88%)
Previous tested 
(percentage of tested) 1.000 (63%) 933 (41%) 2.000 (53%) 100 (37%) 4.033 (52%)
*Male who have Sex with Male. **High-Risk Heterosexual.
were HIV oral test reactive (50/7.865) in five
years, all of them were confirmed by rapid blood
test and by the ELISA and Western Blot conven-
tional test. Almost all (86%) HIV-positive subjects
were homosexual men (MSM), aged between 20-
50, coming from Italy (72%), with a medium-high
education level (60%), and with unsafe sexual
practices (92%). 32% of them were previously
tested for HIV screening (Table 2). All 50 patients
were asymptomatic and without a history of HIV-
related symptoms or pathology. In particular,
none had signs or symptoms of primary HIV in-
fection or serological conversion. They were im-
mediately directed to our clinical department for
all medical needs related to HIV infection and al-
most all are still in treatment programmes at our
HIV Centre.
Evaluating and looking at the EASY test data
from another point of view, that is the distribution
in the different initiatives (Table 3), the events ap-
proached by the largest number of people were
the FreeDay EASY test, carried out each first
Friday of the month in two San Raffaele Points of
Care and one HIV-STDs Prevention Unit, now a
fixed prevention appointment for many people
coming from Milan and the surrounding area. In
fact, during the FreeDay Easy test, a total of 3,738
HIV rapid oral test were performed from 2009 to
date, and 22 new HIV infections were detected,
keeping the average of 0.6% of new HIV infec-
tions diagnosed. The other event approaching
many subjects was the Public event of Milan City
and the 1st December AIDS World Day, during
which 2,276 tests were performed and 12 (0.5%)
new HIV infections were diagnosed. 
The average population tested during the four dif-
ferent initiatives was represented by Italian men
(70%), in employment with a high education lev-
el (61%), 62% of whom were MSM practising un-
safe sex (Table 3). The percentage of subjects pre-
viously tested was on the rise over the past two
years, mainly thanks to the FreeDay Easy appoint-
ment, that ensures an anonymous, fast and easy
screening, much appreciated by the population.
DISCUSSION
The development of rapid tests for the diagnosis
of HIV infection is not only to facilitate access to
testing, overcoming the “barrier” of fear over in-
vasive conventional tests and to reduce HIV trans-
mission, but also and especially to reduce the in-
dividual risk of disease progression and social
costs associated with the diagnosis of “late pre-
senters” (Lee et al., 2007).
Overall, awareness and consciousness of alterna-
tive HIV test methods was limited across all the
interviews, particularly in the first four years of
the project. Previous studies on acceptability and
preference for alternative HIV tests, as well as
misconceptions about the accuracy of the tests
as reported in our analysis suggest that an ap-
propriate information and education about al-
ternative HIV tests has the potential to increase
testing among at-risk and not at-risk individuals
(FDA, 2012).
Some studies have shown that alternative HIV
tests are accepted with a 99% of satisfaction lev-
el and may be preferred when people are edu-
cated about these tests (Gauthier et al., 2012;
Spielberg et al., 2003). Studies looking at adoles-
cents’ preferences for HIV tests have shown that
non-invasive HIV antibody tests (such as oral mu-
cosal transudate) and tests with rapid results were
preferred. Similar studies have been done to look
at the HIV testing preferences of adults. Most par-
ticipants in these studies preferred oral fluid rap-
id testing, followed by rapid testing using blood.
Throughout all of the studies, the least preferred
method was standard blood testing (Branson et
al., 2006; http://www.bhiva.org).
The literature on the costs and the cost-effective-
ness of HIV counselling and testing demonstrates
that the costs of new HIV diagnoses vary ac-
cording to the strategies used to recruit people
for testing (e.g., outreach, partner notification,
and social networks), testing technologies (e.g.,
rapid or conventional HIV testing), and costs in-
cluded in the analysis (e.g., variable vs. fixed
costs).
Some studies specified the costs of identifying
new cases of HIV infection by recruitment strat-
egy (http://www.has-sante.fr). For example, Katz
and colleagues studied a peer-referral approach
for HIV counselling and rapid testing among
MSM in an STDs clinic in King Country,
Washington. They found that the cost per new
HIV diagnosis ranged from $5,600 to $12,000 (ad-
justed to 2005 US dollars value) when the HIV
serological prevalence rates were 4.4% and 1.3%,
respectively. The costs of clinical management of
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late diagnoses have doubled (Katz et al., 2012).
We successfully conducted this rapid HIV testing
and counselling program with the goal of spread-
ing the use of saliva test anonymously and free
of charge. We aimed to facilitate access to test-
ing in alternative settings, to establish if the “sub-
merged” population would access salivary rapid
testing versus the conventional settings. 
In the present study, the non-respondents com-
monly cited concern for accuracy as the reason
for not using rapid tests. The standard blood test
and home collection kit use different collection
methods and specimens and all have been shown
to have sensitivity and specificity greater than
99%. The rapid oral tests, which use a different
testing method, have been shown to have equal-
ly high specificity, and a lower value of sensitivi-
ty, not representing an obstacle, due to the prior-
ity of the saliva test to identify more or less re-
cent new HIV infections (Pavie et al., 2010).
Therefore, the concern that alternative tests may
be less accurate is not supported by experience
with the test and is likely due to lack of knowl-
edge on test performance. This suggests a need
for increased education among high-risk popu-
lations about the accuracy of these tests (FDA,
2012). 
A common reason reported by respondents from
all events for complaining about the low uptake
of the oral test was that it was not offered to them
in conventional settings. Providers might not of-
fer alternative tests if “standard” testing is ac-
cepted by a client. A provider survey to ascertain
the levels of knowledge and situations in which al-
ternative testing may or may not be offered by
physicians and HIV testing centres would help to
determine specific educational needs. 
Our analysis has some limitations because is a
broad approach to offer an easier test in different
settings with a standardized procedure, but it is
not a selection of a target population. Although a
formative research process was conducted to se-
lect locations representative of communities at
risk for HIV infection, sites were not randomly
selected, and therefore our findings may not be
generalizable to all individuals at risk for HIV in-
fection in the areas where the survey was con-
ducted. In addition, our response rate of 5.6%
(7,865 tested/140,000 informed) of interviewed
individuals may introduce some bias if those re-
fusing interviews were different from those ac-
cepting interviews. We did not collect demo-
graphic information from those who declined to
be interviewed and tested, and thus could not
characterize this potential bias. 
The results from this analysis suggest that the
promotion of alternative HIV test screening has
not yet been fully developed as a strategy to in-
crease levels of HIV testing among people at risk
for HIV infection. Increasing awareness of these
alternative tests among individuals at risk and
providers may be an appropriate strategy to in-
crease the numbers of people who know their
serological status. However, our analysis does not
make clear the extent to which availability of al-
ternative HIV tests would increase testing among
those high-risk individuals previously untested
for HIV. This question, which relates most di-
rectly to CDC’s strategic goal of increasing aware-
ness of serological status among people living
with HIV infection, may be answered by ques-
tions in future interview studies on the willing-
ness or intention to test with alternative HIV tests
among individuals untested in the past.
The recent introduction of rapid oral HIV anti-
body testing has completely changed the HIV di-
agnosis approach by facilitating the possibility of
testing millions of people worldwide. The avail-
ability of affordable, point-of-service HIV testing
is especially important, not only in low-income,
high-HIV-burden countries which lack the finan-
cial and technological resources to perform more
sophisticated laboratory-based assays, but also
in developed countries were the HIV prevalence,
morbidity and mortality continue because of lack
of awareness.
Our short experience in Uganda seems confirm
the above suggestion: the high acceptability of the
local population during our preliminary screen-
ing in a small village emphasized the high poten-
tial of the rapid saliva test in low-income coun-
tries, especially in places where there is aware-
ness but a lack of resources (Parisi et al., 2009).
CDC launched the Advancing HIV Prevention
Initiative with the objective to implement new
models for diagnosing HIV infections outside
medical settings, also to reduce the number of
people who do not return for their test results.
The possibility of rapid and more accessible test-
ing methods gives the option of immediate coun-
selling and referral to medical treatment as well
as partner notification (ECDC, 2011). Public
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health agencies should consider strategies to
make rapid tests with well-documented per-
formance characteristics available in epidemio-
logical and clinical settings.
For these reasons, we hope the oral-based rapid
HIV tests could become the gold standard to fa-
cilitate HIV screening access and become the
standard of care and the basis for the national
HIV testing algorithm in many countries with
HIV epidemics to increase the proportion of per-
sons aware of their HIV serological status.
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